Anzeige
Mehr »
Mittwoch, 17.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
178 Leser
Artikel bewerten:
(0)

Nurses from The Children's Hospital of Philadelphia Review History and Recent Advances of Fetal Surgery for Spina Bifida

PHILADELPHIA, Aug. 10, 2012 /PRNewswire-USNewswire/ --Thirty years ago the idea of performing fetal surgery seemed more like science fiction than reality. Today, however, highly sophisticated surgical teams regularly repair spina bifida and other birth defects before birth, and fetal therapy is recognized as one of the most promising fields in pediatric medicine.

(Photo: http://photos.prnewswire.com/prnh/20120810/DC56010)

Spina bifida is the most common birth defect of the central nervous system, affecting about 1,500 babies born each year in the United States. In 2011, research co-led by The Children's Hospital of Philadelphia (CHOP) and published in the New England Journal of Medicine, showed that performing surgery in the womb, months before birth, can substantially improve outcomes, such as mobility, for children with this common, disabling birth defect of the spine.

In a new article in the August 2012 issue of the AORN Journal, published by the Association of periOperative Registered Nurses, nurses from CHOP's Center for Fetal Diagnosis and Treatment review the history of fetal surgery for spina bifida from inception to current practice.

"Our Center's multidisciplinary team has the world's greatest amount of experience performing fetal surgery and as a result, CHOP nurses have had a great opportunity to help advance the field of fetal medicine," said Susan M. Scully, BSN, RN, CNOR. "Specifically, as participants in the landmark Management of Myelomeningocele Study (MOMS), CHOP nurses contributed to making fetal surgery for spina bifida a standard-of-care option for families."

In their article, "Fetal Myelomeningocele Repair: A New Standard of Care," Scully and her co-authors, Maureen Mallon, MBA, BSN, RN, CNOR, Joy C. Kerr, BSN, CNOR, and Allison Ludzia-DeAngelis BSN, RN, provide an overview of the field of fetal surgery, the rationale to prenatally repair spina bifida, the landmark MOMS trial, CHOP's fetal surgery program and the important role perioperative nurses have played in this pioneering treatment.

To read the full article visit: http://bit.ly/ObW4J0

About the Center for Fetal Diagnosis and Treatment at CHOP
The Center for Fetal Diagnosis and Treatment at The Children's Hospital of Philadelphia is an internationally recognized leader in fetal surgery and fetal care. One of the only programs of its kind in the world, it offers a comprehensive breadth of services, including fetal therapy, to support patients from prenatal evaluation through delivery, postnatal care, and long-term follow-up. Established in 1995, the Center has welcomed more than 12,000 expectant parents and received referrals from all 50 states and more than 50 countries. Its multidisciplinary team brings decades of experience to the care and treatment of the fetus and the expectant mother. The Center has performed over 900 fetal surgeries, including complex open procedures for birth defects such as spina bifida; less invasive fetoscopic or ultrasound-guided surgeries for conditions such as twin-twin transfusion syndrome; and specialized coordinated delivery approaches for babies that require surgical intervention while still on maternal-placental life support (EXIT delivery). For more information visit http://fetalsurgery.chop.edu.

About The Children's Hospital of Philadelphia:
The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 516-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

Contact: Ashley Moore
The Children's Hospital of Philadelphia
Phone: (267) 426-6071
MooreA1@email.chop.edu

SOURCE The Children's Hospital of Philadelphia

© 2012 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.